Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy by Saraiya, N. et al.
Systematic review with meta-analysis: recurrence of
hepatocellular carcinoma following direct-acting antiviral
therapy
N. Saraiya1 | A. C. Yopp2 | N. E. Rich1 | M. Odewole1 | N. D. Parikh3 |
A. G. Singal1,4
1Department of Internal Medicine, UT
Southwestern Medical Center, Dallas, TX,
USA
2Department of Surgery, UT Southwestern
Medical Center, Dallas, TX, USA
3Department of Internal Medicine,
University of Michigan, Ann Arbor, MI, USA
4Department of Clinical Sciences, University
of Texas Southwestern, Dallas, TX, USA
Correspondence
Dr. AG Singal, Division of Digestive and
Liver Diseases, University of Texas
Southwestern, Dallas, TX, USA.
Email: amit.singal@utsouthwestern.edu
Funding information
This work was conducted with support from
NCI RO1 CA212008 and RO1 CA222900.
The content is solely the responsibility of
the authors and does not necessarily
represent the official views of the National
Institutes of Health
Summary
Background: Although studies suggest decreased incident hepatocellular carcinoma
(HCC) after direct-acting antivirals (DAA), data are conflicting regarding HCC recur-
rence and aggressiveness in patients who have a history of HCC with complete
response.
Aim: Characterize HCC recurrence patterns after DAA therapy.
Methods: Two reviewers searched MEDLINE and SCOPUS from January 2015 to
December 2017 and identified studies evaluating HCC recurrence patterns following
DAA therapy. A pooled estimate was calculated using the DerSimonian and Laird
method for a random effects model. The study was conducted in accordance with
PRISMA guidelines.
Results: Among 24 studies (n = 1820 patients), the proportion of patients with
HCC recurrence following DAA therapy ranged from 0% to 59% (pooled estimate
24.4%; 95% CI: 18.4%-30.4%). Among 11 full text manuscripts, pooled HCC recur-
rence was 21.9% (95% CI: 16.2%-28.3%). Factors associated with recurrence
included history of prior HCC recurrence and a shorter interval between HCC com-
plete response and DAA initiation. Nine studies comparing DAA-treated and inter-
feron-treated or untreated patients found similar recurrence among DAA-treated
patients. Most (77.8%) patients with HCC recurrence were detected at an early
tumour stage, of whom 64.7% received curative treatment. Study limitations
included heterogeneous cohorts, potential misclassification of HCC absence prior to
DAA, ascertainment bias for recurrence, and short durations of follow-up.
Conclusions: Current data suggest acceptable HCC recurrence rates after DAA ther-
apy, particularly if DAA therapy is delayed at least 6 months after HCC complete
response. However, data characterising HCC recurrence after DAA therapy are of
limited quality, highlighting the need for high quality prospective studies.
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1 | INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-
related death worldwide, with chronic hepatitis C (HCV) being the
most common underlying etiology in the United States and Europe.1
Liver transplantation, surgical resection, and local ablative therapy are
potentially curative and associated with excellent long-term survival
but are limited by tumour recurrence exceeding 50% at 5 years.2
Prior attempts at adjuvant pharmacologic therapy for HCC have
failed to improve survival or reduce recurrence, with the exception of
anti-viral therapy.3 Interferon-based therapy was associated with a
significant reduction in HCC incidence in patients with HCV-related
cirrhosis as well as HCC recurrence after curative therapy.4 The mech-
anism for reduction in HCC recurrence is unclear—whether related to
sustained viral response (SVR) or direct interferon-related immune-
mediated antitumour effect.5 This debate has become more relevant
to the introduction of direct acting antiviral (DAA) therapy, which has
replaced interferon-based therapy for HCV.6 Although studies have
demonstrated improvements in fibrosis and portal hypertension as
well as decreased risk of incident HCC in patients with HCV-related
cirrhosis, some observational studies suggest an increased risk and
aggressiveness of HCC recurrence after DAA therapy.7-10
This issue remains a topic of debate, leading to uncertainty if or
when to treat HCV-infected patients with a history of HCC.11,12 These
data have created fear among patients receiving DAA therapy and
prompted some providers to withhold HCV treatment from patients
with a history of HCC. The European Medicine Agency’s Pharmacovig-
ilance Risk Assessment Committee has required high quality data eval-
uating this association. Given the lack of randomised data evaluating
this association, we are forced to rely on cohort studies and indirect
comparisons across studies. The aim of this systematic review is to
characterize HCC recurrence patterns following DAA-based therapy.
2 | METHODS
2.1 | Literature search and study selection
We searched MEDLINE and SCOPUS databases from January 1, 2015
through December 1, 2017 using search terms: (liver ca$ or hepatocel-
lular ca$ or hcc or hepatoma) and (hepatitis C or HCV) and (interferon-
free or direct-acting antiviral or DAA). We also manually searched
abstracts from the 2016 and 2017 American Association for the Study
of Liver Diseases, European Association for the Study of the Liver, and
International Liver Cancer Association annual conferences. Additional
studies that may have been missed by the electronic search were iden-
tified through manual searching of reference lists from applicable stud-
ies and consultation with experts in the field. If the applicability of an
article could not be determined by title or abstract alone, the full text
was reviewed. Articles and abstracts were independently evaluated
for possible inclusion by 2 authors (N.S. and A.S.) and any uncertainties
were resolved through discussion with another reviewer (N.P.). The
study was conducted in accordance with Preferred Reporting Items
for Systematic Review and Meta-analysis (PRISMA) guidelines.13
Studies were included for analysis if they evaluated HCC recur-
rence after DAA therapy in a cohort of patients with chronic HCV
infection and a history of HCC with complete response. We included
studies with complete response from surgical, local ablative, or locore-
gional therapies; however, we excluded cohorts focusing exclusively
on post-transplant HCC recurrence and studies that included inter-
feron-based regimens in combination with DAAs. Complete response
in studies was typically defined using modified Response Evaluation
Criteria in Solid Tumours (mRECIST), that is, disappearance of arterial
enhancement in all HCC lesions. Studies may have been retrospective
or prospective but were required to report the proportion of patients
with recurrence after DAA therapy. Additional exclusion criteria
included (1) non-English language, (2) nonhuman data, and (3) lack of
original data. If publications reported data using the same cohort of
patients, the study with more complete data was included.
2.2 | Data extraction
Two authors (N.S. and A.S.) independently reviewed and extracted
required information from eligible studies using standardised forms. A
third investigator (N.P.) was available to resolve any discrepancies
between the sets of extracted data. The data extraction form included
the following study design items: geographical location and date of
study, study design (prospective vs retrospective), characteristics and
size of study cohort, inclusion and exclusion criteria, HCC treatment
regimen, median time from HCC treatment to DAA treatment, and
duration of follow-up. In addition, the extraction form recorded the
following primary data: proportion of patients with HCC recurrence
and patterns of recurrence (ie, tumour burden and HCC-directed treat-
ment). Two authors (N.S. and A.S.) independently assessed study qual-
ity using a modified checklist based upon a modified version of the
Newcastle-Ottawa quality assessment scale, with discrepancies
resolved by consensus.14 Studies with <1 year of follow-up or loss to
follow-up exceeding 5% were regarded as high risk of bias.
2.3 | Statistical analysis
The aim of this study was to characterize HCC recurrence patterns
after DAA therapy. For each individual study, the proportion of
patients with HCC recurrence with 95% confidence intervals was cal-
culated. Estimates of effect were pooled using a binomial-normal
model and the DerSimonian and Laird method for a random effects
model. Heterogeneity was initially evaluated graphically by examina-
tion of forest plots and statistically by the inconsistency index (I2), with
values >50% consistent with the possibility of substantial heterogene-
ity.15 Subgroup analyses were planned for HCC detection for prede-
fined subsets of studies based on (i) prospective vs retrospective study
design, (ii) study location, (iii) duration of follow-up (iv) timing of DAA
initiation, and (v) availability of full text manuscripts. We assessed for
presence of heterogeneity between subgroups, with statistical signifi-
cance defined as P < 0.05. We also performed a subgroup analysis
among studies reporting early HCC recurrence after DAA initiation.
We performed univariate and multivariate meta-regression analyses to
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evaluate the potential association between study-level covariates
(study location, study design, sample size, proportion of patients with
early HCC, timing of DAA initiation, and length of follow-up) and HCC
recurrence. A secondary analysis among studies reporting relative
recurrence rates between DAA-treated and untreated patients, in
which we determined a pooled estimate for the relative risk of recur-
rence using a random effects model. Publication bias was evaluated
graphically by funnel plot analysis. Analyses were performed using
STATA 14.0 (StataCorp, College Station, TX, USA).
3 | RESULTS
3.1 | Literature search
Upon review of the 827 titles identified by the search strategy, 63
abstracts were further examined. Twenty-three publications under-
went full-text review to determine their eligibility for the meta-
analysis and 4 were excluded. The remaining 16 studies were selected
after meeting all applicable inclusion criteria. Overall, 20 studies were
excluded because they presented data on HCC occurrence but not
recurrence, 11 had insufficient data for abstraction, 5 had overlapping
cohorts, 4 exclusively characterised post-transplant HCC recurrence,
and 7 studies were excluded for lack of original data (Figure S1).
Finally, review of American Association for the Study of Liver Dis-
eases, European Association for the Study of the Liver, and Interna-
tional Liver Cancer Association conference abstracts identified 7
additional studies and recursive literature searches identified 1 full-
length manuscript and 2 letters to the editor that met inclusion crite-
ria, producing a total of 26 studies.16-39 The study by the ANRS
collaborative study group included 2 distinct cohorts,24 yielding a total
of 27 cohorts. Two included studies reported relative HCC recurrence
rates compared to interferon-treated or untreated patients but did
not report absolute HCC recurrence rates,40,41 yielding 24 studies
with 25 cohorts characterising the primary outcome of absolute HCC
recurrence rates after DAA initiation.
3.2 | Study characteristics
Characteristics of the 24 studies (ie, 25 cohorts) reporting the abso-
lute proportion of patients with HCC recurrence after DAA therapy
are described in Table 1. The majority of cohorts were retrospective
(n = 19) and only available as abstracts or letters to the editor
(n = 14). Thirteen cohorts were conducted in Europe, 10 in Asia, and
2 in the United States. Studies included a total of 1820 DAA-treated
patients, although most cohorts (n = 19) included less than 100
patients, resulting in imprecise estimates for HCC recurrence with
wide confidence intervals. Most patients had achieved HCC com-
plete response after resection or ablation; however, 25%-50% of
patients in some studies had received noncurative therapies, includ-
ing transarterial chemoembolisation (TACE). Duration of follow-up to
assess recurrence ranged from 3 to 36 months, although some stud-
ies defined recurrence from date of HCC treatment and others eval-
uated recurrence from date of DAA initiation. Although most studies
only included single-arm cohorts, 7 of the studies included a com-
parator arm of interferon-treated and/or untreated patients. Two
additional studies did not report the absolute proportion of patients
with HCC recurrence but compared relative recurrence between
DAA-treated patients and interferon-treated or untreated patients,
yielding a total of 9 comparative studies (Table 2).
3.3 | HCC recurrence following DAA therapy
The pooled point estimate for HCC recurrence following DAA ther-
apy was 25.1% (95% CI: 19.4%-31.2%); however, there was signifi-
cant statistical heterogeneity (I2 = 86%) (Figure 1). The proportion of
patients with HCC recurrence varied widely between studies, ranging
from 0% to 59% within 2 years (Table 1). In subgroup analyses,
pooled estimates for HCC recurrence were similar between prospec-
tive and retrospective cohort studies (23.9% vs 25.6%, P = 0.76),
studies with duration of follow-up shorter or longer than 12 months
(21.9% vs 27.6%, P = 0.29), and studies in which HCC recurrence
was assessed starting at DAA initiation vs other times (24.6% vs
26.0%, P = 0.84). However, HCC recurrence was higher in studies
conducted in the United States compared to Europe and Asia (43.3%
vs 22.1% vs 28.9%, P < 0.001). There continued to be significant
heterogeneity, with I2 values remaining greater than 70%, in all sub-
group analyses. Among the 11 studies with data regarding “early”
recurrence, the proportion with recurrence within 6 months ranged
from 5% to 29%, with a pooled proportion of 10.3% (95% CI: 6.3%-
14.4%; I2 = 49%).
Among the 11 studies available as a full text manuscript, the
pooled HCC recurrence rate was 21.9% (95% CI: 16.2%-28.3%),
although there continued to be statistical heterogeneity with
I2 > 75%. In subgroup analyses, pooled estimates for HCC recur-
rence were similar between prospective and retrospective cohort
studies (18.6% vs 22.9%), studies with duration of follow-up shorter
or longer than 12 months (22.6% vs 22.0%), studies in which HCC
recurrence was assessed starting at DAA initiation vs other times
(22.7% vs 21.1%), and studies conducted in Europe and Asia (20.1%
vs 25.7%). There was no association between HCC recurrence and
study location, study design, sample size, the proportion of patients
with early HCC, median time from HCC treatment to DAA initiation,
or median length of follow-up in meta-regression analyses.
The most commonly reported factor associated with increased
recurrence within included studies was the interval between HCC
complete response and DAA initiation. Reig and colleagues found
higher recurrence (41% vs 23%) in patients treated within 4 months
of HCC complete response,21 whereas Ogawa reported this associa-
tion using a cut-off of 1 year (HR: 0.31, 95% CI: 0.10-0.77),20 and
Minimi et al. using a cut-off of 2 years (HR: 0.34).42 Similarly, Kolly
et al. found patients with a longer timeframe between HCC treat-
ment and DAA therapy had significantly lower hazards of recurrence
(HR: 0.91, 95% CI: 0.85-0.96).31 A history of prior HCC recurrence
was also associated with increased risk of HCC recurrence following
DAA therapy (HR: 2.2-2.3), as reported by Minami, Cabibbo, and
Ikeda.17,18,42 Although many studies reported no difference in HCC
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12 months End of DAA
treatment
32 months 14.6 (5.6-29.2)
Cabibbo
201717,a
Italy Prospective 143 (100%) 18  26 Resection 36%
Ablation 46%
TACE 18%
11 months Start of DAA
treatment
8.7 months 20.3 (14.0-27.8)
Ikeda
201718,a




10.7 months Start of DAA
treatment
20.7 months 34.6 (27.9-41.7)
Nagata
201719,a
Japan Retrospective 83 (100%) NR Resection or
ablation
NR HCC treatment 27.6 months 27.1 (18.2-36.9)
Ogawa
201720,a





14.4 months Start of DAA
treatment
17 months 17.5 (11.9-23.9)
Reig
201721,a
Spain Retrospective 77 (97%) 10 (1-369) Resection 36%
Ablation 53%
TACE 10%
11.2 months Start of DAA
treatment
8.2 months 27.3 (17.7-38.6)
Virlogeux
201722,a
France Retrospective 23 (91%) 13 (2-170) Resection 26%
Ablation 61%
Other 13%
7.1 months Start of DAA
treatment
35.7 months 47.8 (26.8-69.4)
Conti
201623,a




12.4 months End of DAA
treatment
5.5 months 28.8 (17.8-42.1)
ANRS
201624,a
France Retrospective 189 (NR) NR NR NR Start of DAA
treatment
20.2 months 12.7 (8.3-18.3)
ANRS
201624,a
France Retrospective 13 (NR) NR NR >3 months Start of DAA
treatment
21.3 months 7.6 (0.2-36.0)
Rinaldi
201625,a
Italy Retrospective 15 (100%) NR Resection 14%
Ablation 86%
11.3 months Start of DAA
treatment
2.8 months 6.7 (0.2-32.0)
Zavaglia
201726




19.3 months Start of DAA
treatment
8 months 3.2 (0-16.7)
Zeng
201627
China Retrospective 10 (100%) NR Ablation 100% NR End of DAA
treatment
15 months 0 (0-25.9)
Torres
201628




7.5 months Start of DAA
treatment
12 months 0 (0-31.2)
Gheoghe
201729
Romania Retrospective 20 (NR) NR NR NR DAA treatment 6 months 20.0 (5.7-43.7)
Granata
201730
Italy Prospective 65 (83%) NR NR 9 months Start of DAA
treatment




Retrospective 56 (NR) NR Ablation,
resection
or TACE
NR HCC treatment 21 months 1-year 19%
2-year 44%
Yasui 201732 Japan Retrospective 46 (NR) NR NR NR End of DAA
treatment
6 months 14.3 (5.4-28.5)




8 months Start of DAA
treatment
14.5 months 47.9 (40.0-55.8)
(Continues)
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recurrence by classic risk factors including degree of liver dysfunc-
tion, tumour burden, or alpha fetoprotein (AFP) levels, each was
found to be associated with higher recurrence in 1 study. Conti
described higher recurrence in those with increased liver stiffness
(OR: 1.19, 95% CI: 1.01-1.39),23 Ogawa and Cabibbo found higher
recurrence in those with a history of multifocal HCC (HR: 2.34, 95%
CI: 1.05-5.39)20 and larger HCC lesions (HR: 2.73, 95% CI: 1.23-
6.06)17 respectively, Minami reported higher recurrence in those
with AFP-L3 >15% (HR 3.08) or DCP >40 mAU/mL (HR: 2.0),42 and
Ogawa found higher recurrence in patients who underwent noncura-
tive procedures such as TACE (HR: 2.31, 95% CI: 1.04-5.15).20
Nine studies compared HCC recurrence in DAA-treated
(n = 947) patients to interferon-treated (n = 210) and/or untreated
(n = 641) patients (Table 2).22,24,30,32,34,37,40,41 Five studies reported
no significant difference in HCC recurrence between DAA-treated
and untreated patients in multivariable analyses, while 2 studies
found significantly lower HCC recurrence among DAA-treated
patients. Among the 5 studies reporting relative risk of recurrence
with 95% confidence intervals, DAA-treated patients had a lower
pooled recurrence risk than untreated patients (OR: 0.55, 95% CI:
0.25-0.85). All 3 studies comparing DAA-treated and interferon-trea-
ted patients reported no difference in HCC recurrence between the
2 groups; however, only unadjusted analyses were reported.
3.4 | HCC recurrence patterns
Patterns of HCC recurrence including tumour burden and HCC-
directed treatment after DAA therapy are detailed in Table 3. The
majority of patients (77.8%, 95% CI: 72.9-82.1) with HCC recurrence
across studies were detected at an early stage, and two-thirds of
those found at an early stage (64.7%, 95% CI: 57.9-71.2) received
curative treatment with liver transplant, resection or ablation. Only 3
studies described response to HCC therapy.18,21,37 Reig et al.
reported that 32% of patients had tumour progression within
6 months of recurrence,21 whereas Singal et al. reported 17% had
progressive disease after HCC-directed therapy37 and Ikeda et al.
observed rapid tumour progression in only 5% of patients.18
3.5 | Quality assessment
Quality assessment of included studies is provided in Table 4. Most
studies had appropriate representativeness of the cohort and expo-
sure ascertainment. There was heterogeneity in cohorts with several
studies including patients with nonearly stage HCC, high AFP levels,
multiple prior HCC recurrences, or treatment with locoregional ther-
apies who are all at higher risk of HCC recurrence than their coun-
terparts. There was also heterogeneity in the length of time
between HCC complete response and DAA initiation, which is asso-
ciated with risk of HCC recurrence. However, some studies required
patients to have HCC complete response for at least 3-6 months,
other studies included patients who were treated immediately after
HCC-directed treatment. Most studies ascertained HCC recurrence
through medical records but only 7 excluded patients with any suspi-
cious nodules prior to DAA initiation and only 5 included prospective
surveillance protocols. There were an additional 11 studies that
explicitly stated they required documented absence of HCC (but not
suspicious nodules) on imaging prior to DAA initiation, and 8 retro-
spective studies reported a recommended surveillance protocol after
HCC complete response but were regarded as medium risk of bias
given potential for underuse of surveillance in clinical practice. Seven
studies did not explicitly state they excluded HCC prior to DAA initi-

























Ohki 201734 Japan Retrospective 20 (100%) 13 (7-25) Ablation 100% 7.6 months HCC treatment 24 months 35.0 (15.4-59.2)
Sangiovanni
201735





12 months Start of DAA
treatment
11.1 months 32.7 (23.7-42.7)





7.2 months HCC treatment 22.7 months 45.9 (39.0-52.9)
Urabe 201736 Japan Prospective 63 (NR) NR NR 24.3 months Start of DAA
treatment
10.9 months 38.5 (26.2-51.2)
Tokoro 201638 Japan Retrospective 22 (NR) NR NR NR Start of DAA
treatment
16.2 months 59.1 (36.4-79.3)
Tsuda 201639 Japan Retrospective 36 (NR) NR NR NR Start of DAA
treatment
11.4 months 25.0 (12.1-42.2)
DAA, direct acting antiviral; HCC, hepatocellular carcinoma; NR, not reported; TACE, transarterial chemoembolisation.
aAvailable as full length manuscript.
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HCC complete response so were regarded as having a high risk of
bias. Most studies had short follow-up periods <1 year as well as
high (>10%) or unknown loss to follow-up. Although comparative
studies performed multivariable or propensity-score matched analy-
ses, there were remaining issues with confounders including degree
of liver dysfunction and immortal time bias.





patients Comparison of recurrence
Virlogeux 201722 France DAA-treated and untreated 23/45 1.7 vs 4.2/100 person-months in DAA-treated and untreated patients
(adjusted HR: 0.24, 95% CI: 0.10-0.55)
ANRS 201624 France DAA-treated and untreated 189/78 0.73 vs 0.66/100 person-months in DAA-treated and untreated patients
(adjusted HR: 1.04, 95% CI: 0.53-2.07)
ANRS 201624 France DAA-treated and untreated 13/66 1.1. vs 1.7/100 person-months in DAA-treated and untreated patients
(adjusted HR: 0.40, 95% CI: 0.05-3.03)
Granata 201730 Italy DAA-treated and untreated 65/186 Time to recurrence: 23.2 vs 23.0 months in DAA-treated and
untreated patients
Yasui 201732 Japan DAA-treated and IFN-treated 46/26 Proportion: 14% vs 22% in DAA-treated and IFN-treated (P = 0.50)
Joko 201740 Japan DAA-treated and IFN-treated 368/148 No difference in early recurrence between DAA-treated and
IFN-treated patients
Ohki 201734 Japan DAA-treated, IFN-treated,
and untreated
20/20/20 35% vs 55% vs 55% in DAA-treated, IFN-treated, and untreated patients
(P = 0.38)
Singal 201737 USA DAA-treated and untreated 207/127 Proportion: 46% vs 50% in DAA-treated and untreated patients (adjusted
OR: 0.80, 95% CI: 0.48-1.35)
Tanaka 201741 Japan DAA-treated, IFN-treated,
and untreated
16/16/119 Lower recurrence in DAA-treated than untreated group (adjusted
HR: 0.56, 95% CI: 0.26-0.97)

























































F IGURE 1 Proportion of patients with
recurrence of hepatocellular carcinoma
following direct-acting antiviral therapy
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4 | DISCUSSION
There is ongoing uncertainty about the potential risks and benefits
of DAA therapy in patients with a history of HCC. In this com-
prehensive systematic review, we found a pooled estimate of
24.4% for HCC recurrence after DAA therapy, although this point
estimate must be interpreted in the context of its wide confidence
intervals, clinical heterogeneity within and between studies, and
methodological limitations of current data. While there are few
comparative studies with interferon-treated or untreated patients,
these data suggest DAA-treated patients have similar if not lower
recurrence than interferon-treated or untreated patients. Most
patients with HCC recurrence across studies were found at an
early stage and underwent curative treatments, suggesting recur-
rence following DAA therapy is not aggressive; however, few data
characterised treatment response or post-recurrence prognosis.
Current studies have notable limitations including risk for misclas-
sification of HCC complete response prior to DAA initiation and
ascertainment bias, precluding definitive conclusions about the risk
of HCC recurrence and highlighting the need for higher quality
data.
Providers and patients must weigh the potential for increased
early HCC recurrence against demonstrated long-term benefits of
DAA therapy. Patients treated for HCC are at risk for both early and
late recurrence, with early recurrence typically related to intrinsic
tumour factors, while late recurrence is associated with cirrhosis-
related factors such as active viremia and degree of liver
dysfunction.43,44 It has been hypothesised that rapid decrease in
HCV viral load with DAAs results in decreased immune surveillance
of microscopic HCC tumour clones and hence an increased risk of
early HCC recurrence.21,45 Conversely, as seen with interferon-based
therapies, successful treatment with DAAs can result in fibrosis
regression and improvements in portal hypertension and liver dys-
function, shown to be the major driver of death in patients with
HCC complete response and untreated HCV infection.46 Further,
DAA therapy may reduce risk of late HCC recurrence, by decreasing
HCV viremia and improving liver function.10,47 Unfortunately, current
studies are limited by short durations of follow-up, precluding ade-
quate characterisation of early vs late recurrence, highlighting a need
for studies with longer durations of follow-up.
Identifying predictors for increased early recurrence may identify
subgroups in whom DAA therapy should be avoided. Few predictors
for early recurrence were consistently reported except history of
prior HCC recurrence and the interval between HCC complete
response and DAA initiation, with shorter intervals being associated
with higher risk of recurrence. Delaying DAA therapy may allow for
longer duration of immune surveillance of existing microscopic HCC
clones. Delaying DAA treatment can also create a longer time to ver-
ify HCC complete response, thereby minimising the chance of mis-
classification bias. The sensitivity of 1-time CT or MRI for small HCC
lesions is low, with sensitivities of only 40%-50% for subcentimeter
lesions and 60%-70% for 1-2 cm lesions.48 Given the lack of urgency
for HCV therapy after HCC complete response, it appears prudent to
wait at least 6 months after HCC complete response to initiate DAA
TABLE 3 Patterns of HCC recurrence after DAA therapy
Author year
Number with HCC
recurrence Tumour burden at time of recurrence HCC-directed treatment
Bielen 201716 6 33% BCLC A, 33% BCLC B,
17% BCLC C, 17% unknown
17% resection
33% TACE and 50% supportive care
Cabibbo 201717 29 62% BCLC A, 21% BCLC B,
7% BCLC C, 10% BCLC D
38% resection or ablation
45% TACE and 7% systemic therapy
Reig 201721 21 90% BCLC A, 10% BCLC B 38% transplant, resection or ablation
19% TACE and 29% systemic therapy
Conti 201623 17 56% unifocal and 70% diameter <2 cm Not reported
Rinaldi 201625 1 100% BCLC A Patient treated with ablation
Granata 201730 18 76% monofocal, 12% multifocal, 12% advanced Not reported
Yasui 201732 6 100% BCLC A Not reported
Minami 201733 78 86% BCLC A, 13% BCLC B, 13% BCLC C 85% resection or ablation
14% TACE and 1% supportive care
Ohki 201734 7 100% BCLC A 86% ablation
14% TACE
Sangiovanni 201735 33 79% BCLC A, 6% BCLC B,
6% BCLC C, 9% unknown
52% transplant, resection or ablation
42% TACE and 6% systemic therapy
Singal 201737 95 74% within Milan Criteria 27% transplant, resection or ablation
54% TACE and 7% systemic therapy
Tokoro 201638 13 Diameter 1.2 cm (0.7-2.0) Not reported
Tsuda 201639 9 56% unifocal, 22% 2-3 nodules, 22% >3 nodules Not reported
BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma.
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therapy, which would typically allow for 2-3 interim multi-phase CT
or MRI scans to confirm durable HCC response.
Notably, most studies to date are single-arm, retrospective
cohort studies with clinical heterogeneity in tumour burden, HCC
treatments leading to complete response, and follow-up periods.
When interpreting the proportion of patients with HCC recurrence
in these single arm studies, it is important to consider the natural
history of HCC after complete response, in which many patients will
have HCC recurrence independent of DAA therapy. HCC recurrence
after complete response can vary substantially depending on which
HCC-directed treatment received. While surgical resection and local
ablative therapies are considered curative, recurrence rates approach
25%-35% within the first year and 50%-60% within 2 years.44,49,50
Further, up to 25%-50% of patients in some studies received TACE,
which is typically not curative and associated with a high risk of
recurrence.51 Further, patients with high-risk tumour characteristics
(eg, multifocal HCC or elevated AFP) have higher recurrence rates
than their counterparts; however, specific data regarding these risk
factors and subgroup analyses were not reported in many studies.
In addition to concerns about clinical heterogeneity within study
populations, we noted potential for misclassification and
ascertainment biases. Several studies did not exclude patients with
suspicious nodules prior to DAA treatment or included patients with
HCC complete response for short periods of time. Therefore, it is
likely some patients already had recurrent HCC at the time of DAA
initiation, which would lead to an overestimation of post-DAA HCC
recurrence. On the other hand, most studies did not include a stan-
dardised surveillance protocol to assess for HCC recurrence. Prior
studies have demonstrated underuse of HCC surveillance in patients
with cirrhosis and the same issue may plague post-treatment
patients, leading to an underestimation of post-DAA recurrence.52,53
These limitations highlight the need for high-quality prospective
studies with strict inclusion criteria and a standardised surveillance
protocol. Although comparative studies suggest recurrence rates
among DAA-treated patients may be similar to interferon-treated
and untreated patients, these analyses are limited by potential for
confounders such as degree liver dysfunction. These studies can also
be limited by immortal time bias, as patients with early recurrence
would typically not receive DAA treatment and therefore would be
over-represented in the untreated group. Given the high prevalence
of limitations in study design, we propose minimum criteria for
future studies in this area (Table 5).














Bielen 201716 * * High High * High
Cabibbo 201717 * * * * High Unknown
Ikeda 201718 * * Medium Medium * *
Ngata 201719 * * High Medium * Unknown
Ogawa 201720 * * * * * Unknown
Reig 201721 * * * Medium High *
Virlogeux 201722 * * * Medium * High
Conti 201623 * * Medium Medium High *
ANRS 201624 * * Medium High * Unknown
ANRS 201624 * * Medium High * Unknown
Rinaldi 201625 * * * Medium High Unknown
Zavaglia 201726 * * * High High High
Zeng 201627 * * High Medium * *
Torres 201628 * * Medium * High Unknown
Gheoghe 201729 * * Medium High High Unknown
Granata 201730 * * * * * Unknown
Kolly 201731 * * High High * Unknown
Yasui 201732 High * High High High Unknown
Minami 201733 * * Medium High * High
Ohki 201734 * * High High * Unknown
Sangiovanni 201735 * * Medium * High High
Singal 201737 * * Medium High * Unknown
Urabe 201736 * * Medium High High Unknown
Tokoro 201638 * * High Medium * Unknown
Tsuda 201639 * * Medium High High Unknown
High, high risk of bias; Medium, intermediate risk of bias; *, low risk of bias.
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A prior systematic review comparing HCC occurrence and recur-
rence following interferon-and DAA-based therapy only included 10
studies characterising recurrence after DAA therapy,54 whereas we
identified 26 studies—including several recent prospective studies.
Waziry and colleagues also included cohorts evaluating post-
transplant recurrence, but we excluded these studies given post-
transplant recurrence could be driven by a different mechanism.
Finally, our study also characterised patterns of HCC recurrence and
highlighted limitations of available data, which informed our recom-
mendations for minimum reporting criteria.
Although our study provides a comprehensive summary of current
literature, limitations of available data hindered our ability to make
strong conclusions about the potential association between DAA ther-
apy and HCC recurrence. In fact, only 3 studies did not have high risk
of bias for at least 1 category of the Newcastle-Ottawa quality assess-
ment scale. There was also significant heterogeneity between studies,
including different patient selection criteria, timing of DAA therapy,
and durations of follow-up. Second, an individual-level meta-analysis
would be more powerful, but we did not have patient-level data to
perform subgroup analyses by degree of tumour burden, type of HCC
treatment, or time between HCC complete response and DAA initia-
tion. Given most data were obtained from small single-centre cohorts,
included studies may suffer from reporting bias. Factors associated
with recurrence were based on descriptive review of included studies,
with differential reporting and meta-analysis of these factors was not
possible. In addition, we excluded non-English studies due to practical
considerations, which may further bias the results.
In summary, there are conflicting data about the potential for
increased HCC recurrence after DAA therapy; however, most studies
have methodological limitations. Ongoing multi-centre retrospective
and prospective studies should provide some insight into this contro-
versial issue; we highlighted some suggested minimum reporting
requirements to avoid the pitfalls of current studies. While awaiting
these data, it is likely prudent to wait at least 6 months after HCC
complete response before initiating DAA therapy.
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